SynthesisJournal of surgical oncology2026
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response.
Synthesis in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Discordance Between Breast and Nodal Pathologic Response in Triple-Negative Breast Cancer: Methodological Considerations and Contemporary Implications.Journal of surgical oncology · 2026Article
- Independent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy.Revista da Associacao Medica Brasileira (1992) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPathological complete response (pCR) after neoadjuvant chemotherapy is associated with improved prognosis in patients with triple-negative breast cancer (TNBC). Differences in pathological response rates between the breast and axillary lymph nodes have prompted interest in understanding response patterns that may, in the future, inform strategies aimed at omitting axillary surgical evaluation. This systematic review aimed to describe and compare the prevalence of breast and axillary pathological responses in TNBC patients treated with neoadjuvant chemotherapy.
methodsThis systematic review was conducted following the PRISMA statement and registered in PROSPERO (ID: CRD498121). Searches were performed in the PubMed, Embase, and Web of Science databases. Studies that described node pathological response (NpCR) and breast pathological response (BpCR) in TNBC patients undergoing neoadjuvant chemotherapy were included. Article selection was independently performed by two reviewers using the Rayyan platform. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale.
resultsAcross the included studies, NpCR rates were consistently higher than BpCR rates in TNBC patients. No study reported higher BpCR compared with NpCR. The mean prevalence of BpCR was 32% (SD 0.6), NpCR was 38.3% (SD 0.9).
conclusionAmong TNBC patients treated with neoadjuvant chemotherapy, NpCR occurs more frequently than BpCR. These findings provide a descriptive overview of current response patterns and may inform future research exploring the safety of omitting axillary surgical evaluation. Factors beyond tumor subtype likely influence response patterns, indicating the need for further research to identify predictive biomarkers and optimize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.